Avant Diagnostics announced today that it has completed its previously announced acquisitions of Amarantus Diagnostics and protein analysis services provider Theranostics Health.
In January, Scottsdale, Arizona-based Avant inked a deal to merge with Amarantus Diagnostics, a subsidiary of therapeutics developer Amarantus Bioscience. The arrangement joins Amarantus’ research-use-only assays for multiple sclerosis and Alzheimer’s disease with Avant’s upcoming microarray-based ovarian cancer diagnostic OvaDx.
Under the terms of that arrangement, Avant acquired all outstanding shares of Amarantus in exchange for 80 million shares of Avant stock, with additional shares to be issued upon certain undisclosed milestones.
Read the story at GenomeWeb